Kyrok raises €3.1M pre-seed for AI operating system targeting pharma and chemical supply chains
The AMW Read
Pre-seed round confirms known trajectory of vertical agent-over-ERP pattern in healthcare/industrial segments; no new player map update or structural shift.
Kyrok raises €3.1M pre-seed for AI operating system targeting pharma and chemical supply chains
Berlin-based industrial AI startup Kyrok has secured €3.1 million in pre-seed funding led by Speedinvest to develop an AI operating system for pharmaceutical and chemical supply chains. Founded in 2025 by Daniel Hofinger and Lukas Bierfreund, the company builds an AI-powered platform that functions as an application layer over existing ERP systems, aiming to help European small and medium-sized enterprises modernize workflows, reduce manual data entry, and capture institutional expertise through industry-specific AI agents. Additional investors include Arve Capital, former SAP CPO Dr. Marcell Vollmer, BCG Partner Dr. André Heeg, and others.
Why it matters: Kyrok's approach represents a verticalized agentic layer atop legacy ERP infrastructure — a variation of the 'agent-over-ERP' pattern that targets highly regulated, knowledge-intensive verticals like pharma and chemicals. This is a recurring substrate dynamic: AI startups are bypassing the challenge of displacing legacy systems by instead building thin agent layers that extract value from existing data without requiring rip-and-replace migrations. For European SMEs in pharma and chemicals — segments with high documentation burdens, batch tracking requirements, and critical institutional knowledge that walks out the door with retiring workers — the value prop is transparent.
Expert take: Kyrok's pre-seed is modest but well-aligned with a clear structural niche. The lead investor Speedinvest has a track record in European B2B SaaS, and the presence of former SAP leadership suggests enterprise distribution pathway thinking. The key question is whether the 'AI OS' framing will deliver sufficient differentiation versus narrower workflow automation tools, and whether the company can achieve the data integration depth required to make agents truly autonomous in pharma-grade compliance environments. European enterprise AI continues to see seed-stage activity in vertical SaaS-adjacent plays, but the capital requirements for enterprise sales cycles and regulatory validation are significant.